Kidney injury associated with telavancin dosing regimen in an animal model.
Antimicrob Agents Chemother. 2015 May;59(5):2930-3
Authors: Tam VH, Ledesma KR, Bowers DR, Zhou J, Truong LD
The elevation of serum creatinine levels is a concern with telavancin therapy. We examined the onset of kidney injury associated with telavancin in an animal model. Urine samples were collected at baseline and daily to determine the concentrations of kidney injury molecule 1 (KIM-1), a marker for early kidney injury. When a clinically relevant exposure of telavancin was given daily to rats, some differences in kidney injury were attributed to the dosing regimen. Further investigations of alternative telavancin dosing regimens are warranted.
PMID: 25712358 [PubMed - in process]